Related Experiment Video
Updated: Jun 22, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma
Wendy A Henderson1, Ravi Shankar, Jessica M Gill
1National Institute of Nursing Research, National Institutes of Health, Bethesda, MD 20892, USA. hendersw@mail.nih.gov
Insights
Hepatocellular carcinoma (HCC) risk is elevated in dialysis patients with chronic hepatitis C virus (HCV) infection. Cirrhosis, alcohol abuse, and Asian race significantly increase HCC development in this population.
Area of Science:
- Nephrology
- Hepatology
- Oncology
Background:
- Chronic hepatitis C virus (HCV) infection affects 3.2 million US individuals, leading to liver transplantation and healthcare burdens.
- The interplay of HCV and other risk factors in hepatocellular carcinoma (HCC) development among patients with chronic kidney disease (CKD) requires further elucidation.
Purpose of the Study:
- To investigate predictors of hepatocellular carcinoma (HCC) in dialysis patients with chronic hepatitis C virus (HCV) infection.
- To identify factors associated with HCC development in this specific patient cohort.
Main Methods:
- Utilized data from the United States Renal Data System (USRDS), extracting information using ICD-9 codes.
- Analyzed demographic variables (gender, race, dialysis duration) and comorbidities (alcohol abuse, drug abuse, HIV, hepatitis B, diabetes, cirrhosis).
Main Results:
- Among 32,806 HCV-infected dialysis subjects, 262 developed HCC.
- Cirrhosis (12x), alcohol abuse (3x), and diabetes (1.3x) were significant HCC predictors.
- Asian race (3x) and increasing age were associated with higher HCC risk, while females had lower risk.
Conclusions:
- Dialysis patients with HCV infection and cirrhosis, alcohol abuse history, or Asian race face the highest risk for HCC.
- Findings highlight the link between HCV and HCC, crucial for managing and monitoring dialysis patients at risk.
Abstract:
Approximately 3.2 million people in the United States have chronic hepatitis C virus (HCV) infection; the primary cause for adult liver transplantation and a significant burden on healthcare resources. The role of HCV and other risk factors in development of HCC in patients with chronic kidney disease is not well defined. We studied predictors of hepatocellular carcinoma (HCC) in dialysis patients with chronic HCV by analyzing factors associated with its development. Data were extracted from the United States Renal Database System (USRDS) using ICD-9 codes. Variables included were gender, race, duration on dialysis and co-morbidities (alcohol abuse, drug abuse, HIV, hepatitis B, diabetes and/or presence of cirrhosis). Among the 32 806 HCV infected subjects, 262 cases had HCC. HCC was 12 times more likely in subjects with cirrhosis (P < 0.001), three times more likely in subjects with alcohol abuse (P < 0.001), and 1.3 times more likely in subjects with diabetes (P = 0.04). Asians were three times more likely (P < 0.001) to have HCC. Females were less likely to have HCC compared to males (P = 0.002). The likelihood of having HCC increased with age (P =0.001). This population-based study demonstrates that among subjects with HCV on dialysis, those with cirrhosis, Asian race and history of alcohol abuse are at highest risk for development of HCC. Furthermore, these findings indicate links between HCV and HCC which are valuable in case management for identifying; monitoring, and managing dialysis patients with HCC.
Related Concept Videos
Hepatitis
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Dialysis
Hemodialysis II: Procedure and Complications
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
